<div class='circular--portrait' style='background:#FF9E01;color: white;font-size:4em;padding-top: 25px;;'>KA</div>
KADIMASTEM is trading at 33.40 as of the 4th of April 2020, which is 4.02 percent decrease since the beginning of the trading day. The stock's open price was 34.8. KADIMASTEM has 53 percent ods of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 30 days. Equity ratings for KADIMASTEM are calculated based on the Macroaxis scoring framework. The performance scores are derived for the period starting the 5th of January 2020 and ending today, the 4th of April 2020. Click here to learn more.
Analyze Filter   Check how we calculate scores

  Performance0 100 


Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. The company was founded in 2009 and is based in Ness Ziona, Israel. KADIMASTEM operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. more on KADIMASTEM
Vice President - FinanceYossi NizharView All
Macroaxis Advice
Macroaxis buy hold or sell recommendation provided in the context of your current investment horizon and risk tolerance.
Horizon: 30 days (very short)Advice
KADIMASTEM (KDST) is traded on Tel Aviv Stock Exchange in Israel and employs 1 people. The company currently falls under 'Micro-Cap' category with current market capitalization of 42.5 M. KADIMASTEM operates under Healthcare sector and is part of Biotechnology industry. The entity has 124.26 M outstanding shares. KADIMASTEM has accumulated about 1.59 M in cash with (21.93 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02.
Check KADIMASTEM Probability Of Bankruptcy

KADIMASTEM Stock Price Odds Analysis

Odds Down 33.4HorizonTargetOdds Up 33.4
18.23%30 days
Based on normal probability distribution, the odds of KADIMASTEM to move above current price in 30 days from now is about 81.72 (This KADIMASTEM probability density function shows the probability of KADIMASTEM Stock to fall within a particular range of prices over 30 days) .

KADIMASTEM Risk Profiles

KADIMASTEM Stock Against Markets

Did you try this?

Run Positions Ratings Now


Positions Ratings

Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
All  Next Launch Module
Please see Stocks Correlation. Please also try Pattern Recognition module to use different pattern recognition models to time the market across multiple global exchanges.
Company logos by clearbit
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page